4,778 Shares in Encompass Health Co. (NYSE:EHC) Purchased by Natixis

Natixis bought a new position in shares of Encompass Health Co. (NYSE:EHC - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 4,778 shares of the company's stock, valued at approximately $441,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in EHC. MassMutual Private Wealth & Trust FSB raised its stake in shares of Encompass Health by 87.8% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock worth $27,000 after buying an additional 137 shares during the last quarter. CBIZ Investment Advisory Services LLC increased its position in Encompass Health by 38.7% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock worth $42,000 after purchasing an additional 127 shares in the last quarter. Tompkins Financial Corp acquired a new position in shares of Encompass Health in the fourth quarter valued at approximately $46,000. V Square Quantitative Management LLC lifted its stake in shares of Encompass Health by 43.8% during the 4th quarter. V Square Quantitative Management LLC now owns 581 shares of the company's stock worth $54,000 after purchasing an additional 177 shares during the period. Finally, Morse Asset Management Inc purchased a new position in Encompass Health during the third quarter worth about $68,000. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Encompass Health

In other news, EVP John Patrick Darby sold 10,000 shares of the business's stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the sale, the executive vice president now directly owns 79,710 shares of the company's stock, valued at $9,149,910.90. The trade was a 11.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Andrew L. Price sold 5,042 shares of Encompass Health stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the transaction, the chief accounting officer now directly owns 69,164 shares in the company, valued at $6,798,129.56. This represents a 6.79 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.10% of the company's stock.

Encompass Health Stock Performance

EHC traded up $1.23 on Wednesday, hitting $117.14. 1,095,188 shares of the company's stock were exchanged, compared to its average volume of 682,089. The firm has a market cap of $11.80 billion, a PE ratio of 26.26, a P/E/G ratio of 2.31 and a beta of 0.87. The stock has a fifty day moving average of $101.07 and a two-hundred day moving average of $98.96. Encompass Health Co. has a twelve month low of $82.38 and a twelve month high of $117.52. The company has a current ratio of 1.05, a quick ratio of 1.04 and a debt-to-equity ratio of 0.84.

Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, topping analysts' consensus estimates of $1.19 by $0.18. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. The business had revenue of $1.46 billion for the quarter, compared to analysts' expectations of $1.43 billion. During the same quarter last year, the company earned $1.12 EPS. The company's revenue for the quarter was up 10.6% compared to the same quarter last year. On average, research analysts anticipate that Encompass Health Co. will post 4.8 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Tuesday, April 1st were issued a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 0.58%. The ex-dividend date was Tuesday, April 1st. Encompass Health's payout ratio is currently 14.05%.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. UBS Group upped their price target on shares of Encompass Health from $117.00 to $130.00 and gave the stock a "buy" rating in a research report on Monday. Barclays increased their price target on Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a report on Friday, April 25th. KeyCorp boosted their price target on Encompass Health from $120.00 to $122.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Truist Financial reissued a "buy" rating and set a $135.00 target price (up from $116.00) on shares of Encompass Health in a research report on Monday. Finally, Royal Bank of Canada increased their price target on Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a report on Monday. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $120.86.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.